Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study aims to investigate gender-specific adaptations to beta2-adrenoceptor stimulation with selective short- and long-acting beta2-agonist with emphasis on skeletal muscle in relation to performance enhancing effects and anti-doping
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Placebo Comparator | Subjects receive placebo treatment |
|
| Long acting beta2-agonist | Experimental | Subjects are treated with long-acting beta2-agonist formoterol |
|
| Short acting beta2-agonist | Experimental | Subjects are treated with short-acting beta2-agonist terbutaline |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Formoterol | Drug | Subjects are treated with daily inhalation of formoterol |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Proteome enrichment | Change in enrichment (measured in muscle biopsies and assessed using GO annotations) | Baseline and 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Body composition | Change in body composition (measured by dual energy x ray absorptiometry) | Baseline, 2 weeks, 4 weeks and 6 weeks |
| Maximal oxygen consumption (VO2max) | Change in VO2max (measured during bike ergometer cycling to exhaustion) |
| Measure | Description | Time Frame |
|---|---|---|
| Drug exposure | Measured in urine using enantiomeric analysis | Day 1-14 and day 49-56 |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| August Krogh Building | Recruiting | Copenhagen | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006984 | Hypertrophy |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068759 | Formoterol Fumarate |
| D013726 | Terbutaline |
| ID | Term |
|---|---|
| D004983 | Ethanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Terbutaline |
| Drug |
Subjects are treated with daily inhalation of terbutaline |
|
| Placebo | Other | Subjects are treated with placebo |
|
| Baseline, 2 weeks, 4 weeks and 6 weeks |
| D000588 |
| Amines |